Grace Therapeutics, Inc. (GRCE): Total Assets
$66.65M
As of 2026-03-31
$50.07M
As of 2026-06-30
-5.6%
3-year compound annual growth
+1.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $66.65M | -7.4% | 2026-06-18, Balance as of period end |
| 2025-03-31 | $71.99M | -1.8% | 2026-06-18, Balance as of period end |
| 2024-03-31 | $73.30M | -7.4% | 2025-06-23, Balance as of period end |
| 2023-03-31 | $79.12M | -38.5% | 2024-06-21, Balance as of period end |
| 2022-03-31 | $128.62M | +105.9% | 2023-06-23, Balance as of period end |
| 2021-03-31 | $62.46M | +173.3% | 2022-06-21, Balance as of period end |
| 2020-03-31 | $22.85M | -38.1% | 2021-06-22, Balance as of period end |
| 2019-03-31 | $36.90M | n/a | 2020-06-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $66.65M | -7.4% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $68.49M | -30.2% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $69.40M | -45.3% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $71.12M | +3.2% |
| Rallybio Corp (RLYB) | 2025-12-31 | $62.26M | -8.6% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $62.12M | -45.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $61.95M | -32.7% |
Compare GRCE, CNTX, SPRO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗